Fosun Pharma and MingMed Achieve Key Regulatory Milestones for Novel Therapies
核心洞察
Fosun Pharma's subsidiary, Jisimei Pharmaceutical, has received marketing approval in China for its Oxaliplatin Injection, a chemotherapeutic agent developed for cancer treatment.
MingMed Biotechnology (搜索)'s subsidiary, Claruvis Pharmaceutical, has secured FDA IND approval for YY003, a liquid formulation of recombinant Botulinum Toxin Type A (BoNT/A).
YY003, presented in a pre-filled syringe, is intended for treating glabellar lines (搜索) and offers a potentially safer and more convenient option for BoNT/A users.
Shanghai Fosun Pharmaceutical and MingMed Biotechnology (搜索) have both announced significant regulatory achievements that promise to advance treatment options in oncology and aesthetics, respectively.
Fosun Pharma's Oxaliplatin Injection Approved in China
Fosun Pharma's subsidiary, Jisimei (Wuhan) Pharmaceutical Co., Ltd., has received marketing registration approval from China’s National Medical Products Administration (NMPA) for its Oxaliplatin Injection. This independently developed drug is designed for use as a chemotherapeutic agent. Oxaliplatin is a platinum-based chemotherapy drug widely used in the treatment of various cancers, particularly colorectal cancer (搜索). The approval marks a significant step in expanding Fosun Pharma's oncology portfolio and providing new treatment options for patients in China.
MingMed's Recombinant Botulinum Toxin Type A Receives FDA IND Approval
MingMed Biotechnology (搜索), through its partially owned subsidiary Claruvis Pharmaceutical Co., has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for YY003. YY003 is the world's first liquid formulation of recombinant Botulinum Toxin Type A (rBoNT/A), packaged in a pre-filled syringe, and is being developed for the treatment of glabellar lines (搜索) (frown lines).
According to Dr. Wu Yang, Chief Scientific Officer of Claruvis, this liquid formulation of rBoNT/A offers a safer and more convenient option for users. The combination of a highly effective product and its ease-of-use design aims to provide an optimized solution for BoNT/A users. Claruvis Pharmaceutical has already completed a Phase III clinical trial for the treatment of medium to severe glabellar lines (搜索), achieving all study endpoints. The company has also dosed the first patient in a Phase II clinical trial in China for the treatment of adult upper arm spasm, utilizing recombinant BoNT/A for this therapeutic indication. Furthermore, Claruvis has initiated its first Biologics License Application (BLA) in China, supported by comprehensive Phase I, II, and III clinical results.